NASDAQ:KZR

Kezar Life Sciences Stock News

Healthcare > Biotechnology

Buy KZR

*Your capital is at risk

$7.29

+0 (+0%)

At Close: Jun 10, 2026

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

04:01pm, Tuesday, 12'th Nov 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

10:58am, Tuesday, 05'th Nov 2024

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Kezar Life Sciences, Inc. (Nasdaq: KZR) concerning the Company and its directors' and officers' possib

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

08:30am, Monday, 28'th Oct 2024

Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

08:35am, Thursday, 17'th Oct 2024

Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update

08:30am, Thursday, 17'th Oct 2024

What Makes Kezar Life Sciences (KZR) a New Buy Stock

01:00pm, Tuesday, 15'th Oct 2024

Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal

08:30am, Thursday, 10'th Oct 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (“Kezar” or the “Company”) (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to tr

US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial

05:11pm, Friday, 04'th Oct 2024

The U.S. Food and Drug Administration has placed a clinical hold on Kezar Life Sciences' trial of experimental drug for lupus, the company said on Friday.

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

05:00pm, Friday, 04'th Oct 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated

Kezar Life Sciences halts mid-stage trial for lupus treatment

08:46am, Monday, 30'th Sep 2024

Kezar Life Sciences said on Monday it was stopping enrollment of new patients and dosing of ongoing patients in its mid-stage study for treating a symptom of lupus, following the recommendation of an

Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients

08:30am, Monday, 30'th Sep 2024